Illustration of cancer cells and tumor microenvironment–deregulated miRNA target networks leading to tumor growth and progression. Illustration of cancer.

Slides:



Advertisements
Similar presentations
Immune dysfunction & its consequences
Advertisements

Nanoparticle-Based Gene Delivery Systems for Anti-Inflammatory Therapy Michelle Gee, YSP Student, Wellesley High School Yasmeen Elaywan, YSP Student, Boston.
Companion PowerPoint slide set Obesity-associated breast cancer risk: a role for epigenetics? This teacher slide set was created by Dana Haine, MS, of.
FasDR (CD95) in many cancers, in particular Non-Hodgkin’s Lymphoma Benjamin Badger.
Companion PowerPoint slide set Obesity-associated breast cancer risk: a role for epigenetics? This teacher slide set was created by Dana Haine, MS, of.
Natural History, Response to Treatment
Elke Pogge von Strandmann, Silke Reinartz, Uwe Wager, Rolf Müller 
Kusumawadee Utispan, Sittichai Koontongkaew 
Snail-overexpressing cancer cells modulates tumor-associated macrophages through promoting M2 polarization and suppressing inflammasome activation Speaker:
A Novel Link between Inflammation and Cancer
Settling a Nervous Stomach: The Neural Regulation of Enteric Cancer
Andrea L Kasinski, Frank J Slack  Molecular Therapy - Nucleic Acids 
Inflammation and Colon Cancer
Fig. 2. The AngII/AT1R axis regulates the tumor stroma and contributes to an immunosuppressive microenvironment. The AngII/AT1R axis regulates the tumor.
K. Lenhard Rudolph, Daniel Hartmann, Oliver G. Opitz  Gastroenterology 
Minoti V. Apte, Jeremy S. Wilson, Aurelia Lugea, Stephen J. Pandol 
Therapeutic targeting of the tumor microenvironment
Elke Pogge von Strandmann, Silke Reinartz, Uwe Wager, Rolf Müller 
Genomic alterations in breast cancer cell line MDA-MB-231.
Mesenchymal Cells in Colon Cancer
Volume 26, Issue 1, Pages 1-2 (July 2014)
Hiding in Plain Sight: How Cancer Evades the Immune System
Does CSF1R Blockade Turn into Friendly Fire?
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
Macrophages and Therapeutic Resistance in Cancer
Diagnostic approaches to measure the impact of cancer therapies on clonal evolution. Diagnostic approaches to measure the impact of cancer therapies on.
Copy-number alterations in an archival breast cancer sample.
Bhagelu Ram Achyut, Li Yang  Gastroenterology 
Macrophages and Therapeutic Resistance in Cancer
Ning Li, Sergei I. Grivennikov, Michael Karin  Cancer Cell 
The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.
Corrupted tensional homeostasis accompanies tumor progression.
MicroRNAs in Tfh Cells: Micromanaging Inflammaging
Giulio Francia, Urban Emmenegger, Robert S. Kerbel  Cancer Cell 
Volume 154, Issue 1, Pages (January 2018)
Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.
CCL5 is critical for the activity of CAFs and miR-CAFs.
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 4 Role of exosomes in the pathogenesis of alcoholic hepatitis
Tumor Promotion via Injury- and Death-Induced Inflammation
Schematic model of effector pathways that mediate tumor suppression by p53. Schematic model of effector pathways that mediate tumor suppression by p53.
Juan R. Cubillos-Ruiz, Sarah E. Bettigole, Laurie H. Glimcher  Cell 
Frances Balkwill, Kellie A. Charles, Alberto Mantovani  Cancer Cell 
Neutrophils, Wounds, and Cancer Progression
Deciphering and Reversing Tumor Immune Suppression
Proposed spiral model for prostate cancer progression.
Sterile Inflammation Fuels Gastric Cancer
If one assumes that spontaneous mutations can occur with approximately each 20 cell divisions (about 1 million cells), and assuming that mutations provide.
Macrophage Classes and Roles in Immunity
Suggested model of integrated regulation of CCL2 by miRNAs and TFs in human adipocytes and macrophages. Suggested model of integrated regulation of CCL2.
PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.
Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.
Influence of the tumor microenvironment on FL
Normalizing the tumor microenvironment
Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.
Biomechanical force may promote tumor progression by establishing an aggressive tumor cell hierarchy. Biomechanical force may promote tumor progression.
TFAP2A knockdown inhibits cell growth by targeting HIF-1α signaling.
Effect of miRNA mimic on platinum sensitivity.
The Role of TIPE2 Protein in Invasive Breast Carcinoma
PI3Kγ promotes macrophage PDGF-BB expression to control PDAC fibrosis.
The critical roles of miR-23a and miR-27a in colorectal cancer progression. miR-23a primarily increases cell motility through downregulation of its target.
Tumorigenicity of GR CAFs
Microbial sensors and responders in colorectal cancer.
Immune escape mechanisms in cancer.
Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.
Summary of the experimental strategy and key findings of Mitra and colleagues (10). Summary of the experimental strategy and key findings of Mitra and.
Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.
A, schematic representation of some of the major cell types in the stroma and the TME that respond to cytokines via STAT3 (green, stimulation; red, inhibition)
Immunological effects of anticancer therapy.
Stable IL-10: A New Therapeutic that Promotes Tumor Immunity
Presentation transcript:

Illustration of cancer cells and tumor microenvironment–deregulated miRNA target networks leading to tumor growth and progression. Illustration of cancer cells and tumor microenvironment–deregulated miRNA target networks leading to tumor growth and progression. A, MiRNAs play a very important role in the transformation of normal fibroblasts (NF) to CAFs. For example, miR-320 targets ETS2 and controls oncogenic secretome secretion. This oncogenic secretome converts NFs to CAFs in the tumor microenvironment, leading to increased tumor growth via inflammation. B, inflammation in the tumor microenvironment results in alterations in several key miRNAs, such as Let-7 and miR-155, which target a multitude of mRNAs that are involved in proinflammatory signaling. C, macrophages (MAC), T cells, and dendritic cells, all of which are important immune cells found in the tumor microenvironment, deregulate miRNAs that promote tumor growth. D, key challenges in developing miRNA therapeutics include developing novel tumor-targeting nanoparticle delivery systems and better stable miRNA mimics or anti-miRNAs. Rajesha Rupaimoole et al. Cancer Discov 2016;6:235-246 ©2016 by American Association for Cancer Research